NCT04062981View on ClinicalTrials.gov

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 3, 2019

Primary Completion Date

December 14, 2022

Study Completion Date

December 14, 2022

Conditions
Lennox Gastaut Syndrome
Interventions
DRUG

Carisbamate

An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)

Trial Locations (5)

21210

Johns Hopkins Hospital, Baltimore

84113

The University of Utah School of Medicine - Primary Children's Hospital (Primary Children's Medical Center), Salt Lake City

97239

Oregon Health and Science University, Portland

98055

UW Valley Medical Center, Renton

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

SK Life Science, Inc.

INDUSTRY

NCT04062981 - Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome | Biotech Hunter | Biotech Hunter